[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Li J, Ma S, Kang S, Xie J, Sheng X, Luo R: [Evaluation on survival in locally advanced non-small cell lung cancer (NSCLC) for multimodality treatment with or without operation]. Zhongguo Fei Ai Za Zhi; 2005 Dec 20;8(6):535-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation on survival in locally advanced non-small cell lung cancer (NSCLC) for multimodality treatment with or without operation].
  • BACKGROUND: It is uncertain that the effect of multimodality treatment with operation on survival for locally advanced non-small cell lung cancer (NSCLC).
  • The aim of this study is to evaluate the effect of multimodality treatment with or without operation on survival for locally advanced NSCLC.
  • Arm A (n=56): 39 cases were at stage IIIA, and 17 at stage IIIB; Median KPS was 80 (range from 70 to 90 ); Multimodality treatment program included operation, chemotherapy, radiotherapy and traditional Chinese herb medicine.
  • Preoperative or adjuvant chemotherapy regimens included MVP (mitomycin C, vindesine, cisplatin), NP (vinorelbine, cisplatin), TC (paclitaxel, carboplatin), GP (gemcitabine, cisplatin), which were repeated every 4 weeks for 4-6 cycles.
  • Arm B (n=58): 23 cases were at stage IIIA, and 35 at stage IIIB; Median KPS was 70 (range from 60 to 90); Treatment program was the same approximately as arm A except for no operation.
  • (1) Metastatic locations in follow-up, in turn, showed as: lymph node, pleural-lung, bone, brain, liver, pericardium, skin and adrenal;.
  • (1) Metastatic locations in follow-up, in turn, showed as: lymph node, pleural-lung, bone, brain, liver, pericardium, skin, adrenal, pancreatic and esophageal metastasis;.
  • CONCLUSIONS: Compared with non-operative multimodality treatment, operative multimodality treatment including lobectomy or pneumonectomy with mediastinal lymph node dissection can remarkably improve the survival in patients with locally advanced NSCLC.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21208544.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Kim KS, Na KJ, Kim YH, Ahn SJ, Bom HS, Cho CK, Kim HJ, Kim YI, Lim SC, Kim SO, Oh IJ, Song SY, Choi C, Kim YC: Surgically resected isolated hepatic metastasis from non-small cell lung cancer: a case report. J Thorac Oncol; 2006 Jun;1(5):494-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically resected isolated hepatic metastasis from non-small cell lung cancer: a case report.
  • We treated a patient with non-small cell lung cancer (NSCLC) and an isolated hepatic metastasis.
  • He was a 56-year-old male who underwent right pneumonectomy after concurrent chemoradiation therapy (etoposide+cisplatin) with the diagnosis of stage IIIA squamous cell lung carcinoma.
  • Hepatic segmentectomy was performed, and the pathology showed squamous cell carcinoma.
  • Adjuvant chemotherapy with five cycles of gemcitabine and cisplatin was also given.
  • This shows that the surgical resection of an isolated hepatic metastasis may be an option in carefully selected patients with NSCLC without evidence of disease outside the liver.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409905.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Zwitter M, Kovac V, Smrdel U, Strojan P: Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol; 2006 Sep;1(7):662-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
  • We here present experience from a phase I-II clinical trial for patients with locally advanced non-small cell lung cancer (NSCLC) treated with hyperfractionated accelerated radiotherapy and concurrent low-dose gemcitabine.
  • METHODS: Eligible patients had locally advanced inoperable NSCLC without pleural effusion, Eastern Cooperative Oncology Group performance status 0-1, were chemotherapy naïve and had no previous radiotherapy to the chest, and had adequate hematopoietic, liver, and kidney function.
  • Routine brain computed tomography was not performed, and positron emission tomography/computed tomography was not available.
  • Treatment consisted of three parts: induction chemotherapy with gemcitabine and cisplatin in standard doses, local treatment with concurrent chemotherapy and radiotherapy, and consolidation chemotherapy.
  • Patients were irradiated with opposed AP-PA and oblique fields, using 2.5-D treatment planning.
  • Although corrections for inhomogeneous tissue were made, volume of total lung receiving > or =20 Gy (V20) could not be determined.
  • The trial started as phase I, aimed to determine the dose-limiting toxicity and maximal tolerated dose (MTD) for concurrent hyperfractionated radiotherapy (1.4 Gy twice daily) and gemcitabine 55 mg/m twice weekly as a radiosensitizer.
  • RESULTS: Twenty-eight patients with NSCLC, nine patients with stage IIIA, 16 patients with IIIB, and three patients with an inoperable recurrence after previous surgery, entered the trial.
  • The first 12 patients entered Phase I of the trial at the initial level of 42 Gy in 30 fractions in 3 weeks.
  • Dose-limiting toxicity was acute esophagitis; 47.6 Gy in 34 fractions in 3.5 weeks was the MTD for this regimen of concurrent chemotherapy and radiotherapy.
  • Among the long-term survivors, one was in the group irradiated to 42 Gy and six in the groups irradiated to 47.6 Gy.
  • The high incidence of brain relapse emphasizes the need for careful screening for unsuspected brain disease before treatment and the importance of clinical studies on prophylactic cranial irradiation for patients with locally advanced NSCLC.
  • Although the small number of patients in this study precludes any definitive conclusion, it appears that our program of concurrent chemotherapy and radiotherapy offers a chance for disease control at least comparable to previously described programs for inoperable lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / radiotherapy. Radiation-Sensitizing Agents / adverse effects
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Radiation Injuries / etiology. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409933.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Tsavaris N, Kosmas C, Zorzos H, Lazaris A, Vadiaka M, Dimitrakopoulos A, Siakantaris MP, Rokana S, Papalambros E, Pangalis GA, Davaris P: Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. Oncol Rep; 2004 Apr;11(4):899-903
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.
  • We examined the outcome of patients who developed breast cancer after curative chemotherapy (CHOP) for aggressive non-Hodgkin's lymphoma (NHL) in comparison to the outcome of a retrospectively selected matched-pair group of patients with de novo breast cancer, and evaluated the role of drug resistance-related protein (MDR, MRP, LRP) expression in breast cancer tissue.
  • Twenty-two patients presented with breast cancer (BC) in complete remission after CHOP for NHL.
  • The median age was 62 (49-70) years, each had high/intermediate grade B-cell NHL treated with 6 courses of CHOP, and were in complete remission.
  • These patients were compared to a matched-pair group of de novo BC patients selected from our database over the same time period.
  • Breast cancer tissue was stained by immunohistochemistry for drug resistance proteins LRP, MRP, and MDR.
  • Breast cancer developed after a median of 26 (9-49) months of NHL diagnosis; breast tumor grades 1-2 were seen in 12, and grade 3 in 10 patients; 15 were negative and 7 weakly positive for estrogen and progesterone receptors.
  • Twelve patients were stage IIIA/B, and 10 stage IV and were treated with conventional chemotherapy regimens.
  • All progressed early in liver (n=13), brain (n=9), lung (n=6), bone (n=8), lymph nodes (n=7) and soft tissue (n=5), and received second-line chemotherapy with mitomycin-C + vinblastine or taxanes.
  • Time from NHL to breast cancer development was 19 (14-27) months in patients with positive drug resistance proteins (group A), and 37 (26-56) months in patients with 1 or 2 positive resistance proteins (group B) (p<0.001).
  • In patients with stage IIIA/B disease, there was no difference between the examined and control matched-pair group in median TTP, but there was in overall survival (OS) (23 vs 36 months, p=0.029).
  • Patients in the control matched-pair group had more prolonged OS when compared to group A patients who developed BC in <24 months from NHL to BC (p=0.017).
  • We conclude that breast cancer developing shortly after a complete response in NHL, is an aggressive disease variant with minimal potential for response to conventional chemotherapy.
  • Analysis of drug resistance mechanisms concerning MDR, MRP and LRP indicates that most of these patients have BC that overexpress these proteins leading to the suggestion that these mechanisms might be a part of the aggressive disease phenotype and partially explain the poor outcome.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Drug Resistance, Neoplasm. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunochemistry. Membrane Transport Proteins / analysis. Membrane Transport Proteins / metabolism. Middle Aged. Multidrug Resistance-Associated Proteins / analysis. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoproteins / analysis. P-Glycoproteins / metabolism. Prednisone / therapeutic use. Prognosis. Protein Tyrosine Phosphatases / analysis. Protein Tyrosine Phosphatases / metabolism. Receptor-Like Protein Tyrosine Phosphatases, Class 4. Receptors, Cell Surface / analysis. Receptors, Cell Surface / metabolism. Retrospective Studies. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15010892.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoproteins; 0 / Receptors, Cell Surface; 0 / multidrug resistance-associated protein 2; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.1.3.48 / PTPRA protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 4; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


5. Otsuka S, Inagaki M, Nishie M, Hamano R, Tokunaga N, Takahashi K, Tsunemitsu Y, Miyoshi K, Iwakawa K, Takahashi M, Iwagak H: [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2166-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
  • A 25-year-old man with RS rectal cancer received a radical resection of the original tumor and lymph node dissection.
  • Oral tegafur/uracil (UFT)/Leucovorin (LV) therapy has been used for adjuvant chemotherapy, as the pathological Stage was T3N1M0, Stage IIIa.
  • After 10 months from operation, multiple liver metastases were recognized and not resectable.
  • So a systemic chemotherapy by mFOLFOX6+bevacizumab was begun via CV port.
  • After 5 courses of mFOLFOX6+bevacizumab, abdominal CT revealed liver metastases showed remarkable reduction in size.
  • Pathological findings of S6 segment revealed no residual cancer cells, indicating the histological effect of mFOLFOX6+bevacizumab was Grade 3.
  • And no liver damage was recognized.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037358.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


6. Aoyagi H, Uetake H, Ishikawa T, Kobayashi H, Higuchi T, Yasuno M, Sugihara K: [A case report of lipoma-like tumor during hepatic arterial infusion chemotherapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2141-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of lipoma-like tumor during hepatic arterial infusion chemotherapy].
  • The patient was a 65-year-old male, who had been performed partial resections of the colon (descending colon cancer and rectal cancer: Stage IIIa).
  • Hepatic arterial infusion chemotherapy was started, and a complete response for liver metastases had been continuing for 2 years.
  • On the seventh month after the hepatic arterial infusion chemotherapy was started, a lipoma-like tumor of approximately 10 cm was found under the diaphragm on the left side.
  • Two years and two months after hepatic arterial infusion chemotherapy was begun, the patient was hospitalized for excision of the tumor.
  • The histopathological findings showed that the tumor under the left diaphragm was composed of adipose tissue with coagulative necrosis.
  • The existing adipose tissue was thought to have necroses and had become encapsulated.
  • We speculated that the lipoma-like tumor was formed by the angitis with the change of the drug distribution.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hepatic Artery. Lipoma / complications. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Humans. Infusions, Intra-Arterial. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106550.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Newman E, Marcus SG, Potmesil M, Sewak S, Yee H, Sorich J, Hayek M, Muggia F, Hochster H: Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg; 2002 Mar-Apr;6(2):212-23; discussion 223
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
  • We examined the role of neoadjuvant therapy in downstaging locally advanced gastric cancer.
  • Patients with T > or =3 tumors and/or node-positive disease by preoperative clinical staging were eligible for entry.
  • Neoadjuvant therapy consisted of two cycles of CPT-11 (75 mg/m(2)) with cisplatin (25 mg/m(2)) weekly four times every 6 weeks.
  • This was followed by resection with D2 lymph node dissection and two cycles of intraperitoneal chemotherapy with floxuridine and cisplatin.
  • Induction chemotherapy was well tolerated with major toxicities being neutropenia and diarrhea.
  • One patient progressed to stage IV disease during induction chemotherapy and did not undergo surgery.
  • One patient had undetected stage IV disease (liver) and underwent a palliative R2 resection.
  • Postoperative pathologic staging yielded 16% T3 lesions compared to 85% before treatment based on clinical staging; postoperative American Joint Committee on Cancer staging yielded 37% stage IIIA disease compared to 70% stage IIIA before treatment.
  • We conclude that CPT-11-based neoadjuvant therapy downstages locally advanced gastric cancer.
  • Further follow-up is necessary to determine the ultimate impact of this combination therapy on recurrence and survival.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Biopsy, Needle. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Gastrectomy. Gastroscopy. Humans. Injections, Intraperitoneal. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Nov 1;86(9):1657-68 [10547537.001]
  • [Cites] Eur Radiol. 2000;10 (12 ):1877-85 [11305564.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):583-92 [8239772.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1260-2 [8983624.001]
  • [Cites] Curr Opin Oncol. 1996 Jul;8(4):321-8 [8869808.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] World J Surg. 1988 Jun;12(3):374-81 [3400248.001]
  • [Cites] Ann Oncol. 1992 Feb;3(2):149-54 [1606086.001]
  • [Cites] Endoscopy. 2001 Feb;33(2):158-66 [11272218.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):290-4 [9264578.001]
  • [Cites] Am Surg. 2000 Sep;66(9):827-31 [10993609.001]
  • [Cites] Surgery. 1996 Jun;119(6):611-4 [8650600.001]
  • [Cites] Jpn J Surg. 1981 Mar;11(2):127-39 [7300058.001]
  • [Cites] J Clin Oncol. 1996 Jun;14 (6):1818-28 [8656250.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3558-85 [11032599.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Jun;21(7):1033-8 [8210254.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):878-80 [11286464.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):45-50 [10674448.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):121-30 [10550836.001]
  • [Cites] Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):52-4 [11301842.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Surg Endosc. 1996 Oct;10(10):996-9 [8864093.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • [Cites] Cancer. 1997 May 1;79(9):1767-75 [9128994.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12 ):3858-65 [9850031.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • (PMID = 11992807.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16087; United States / NCRR NIH HHS / RR / M01RR00096
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP: Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer; 2001 Dec 1;92(11):2902-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
  • BACKGROUND: Treatment options for patients with recurrent nonsmall cell lung carcinoma (NSCLC) remain limited as a result of poor activity of older agents after platinum-based therapy.
  • METHODS: Patients with advanced NSCLC (Stage IIIB-IV), a World Health Organization performance status (PS) < or = 2, prior paclitaxel plus platinum-based chemotherapy, and unimpaired hematopoietic and organ function were eligible.
  • Chemotherapy was administered as follows: gemcitabine 1000 mg/m(2) was administered on Days 1 and 8 followed by docetaxel 100 mg/m(2) on Day 8, and this regimen was recycled every 21 days.
  • Prophylactic granulocyte-colony stimulating factor was administered on Days 10-14 or until the patient achieved a white blood cell count > or = 5000/microL.
  • Four patients had Stage IIIA disease, 17 patients had Stage IIIB disease, and 22 patients had Stage IV disease.
  • Histologies included 19 patients with adenocarcinoma, 18 patients with squamous cell carcinoma, and 3 patients with large cell carcinoma.
  • Metastatic sites included lymph nodes in 28 patients, bone in 6 patients, liver in 5 patients, brain in 5 patients, lung nodules in 8 patients, adrenals in 7 patients, and other sites in 3 patients.
  • All patients had received prior paclitaxel plus platinum-based treatment; 28 patients had received prior paclitaxel, ifosfamide, and cisplatin.
  • The median time to disease progression was 6 months (range, 1.0-20.0+ months), and the median survival was 8.5 months (range, 1.5-20.0+ months).
  • CONCLUSIONS: The combination of gemcitabine and docetaxel is active and is well tolerated in patients with advanced NSCLC who have failed prior taxane plus platinum chemotherapy.
  • This regimen represents a tolerable and effective combination to apply in the palliative treatment of patients with recurrent NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Patient Compliance. Platinum / therapeutic use. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11753965.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 49DFR088MY / Platinum; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Hirahara K, Tanaka J, Itoh R, Kuriyama H, Tanaka H, Kagamu H, Yoshizawa H, Gejyo F: [Combination of cisplatin and vinorelbine as adjuvant chemotherapy in non-small cell lung cancer patients--feasibility assessment of 5 consecutively treated patients]. Gan To Kagaku Ryoho; 2008 Jan;35(1):109-11
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of cisplatin and vinorelbine as adjuvant chemotherapy in non-small cell lung cancer patients--feasibility assessment of 5 consecutively treated patients].
  • Post-operative adjuvant chemotherapy(POAC)combining cisplatin(CDDP)and vinorelbine(VNR)for non-small cell lung cancer(NSCLC)patients is considered as a standard regimen.
  • Three male and 2 female patients were enrolled, with post-operative stage of IIB/IIIA/IIIB in 1/2/2 patients, respectively.
  • The regimen was aimed to complete 4 cycles, and 4 patients have completed the treatment without reducing the doses.
  • Average treatment interval was 23 days.
  • Four patients experienced grade(Gr)4 neutropenia, and 1 patient had Gr 3 liver damage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195537.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


10. Kwon HC, Kim MC, Kim KH, Jang JS, Oh SY, Kim SH, Kwon KA, Lee S, Lee HS, Kim HJ: Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol; 2010 Dec;6(4):278-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
  • We evaluated the efficacy and toxicity of adjuvant chemoradiation versus chemotherapy in completely resected locally advanced gastric cancer.
  • METHODS: Patients with stage IIIA, IIIB and IV (without metastasis) gastric cancer were treated with chemoradiation and 5-fluorouracil/cisplatin (FP) (arm A) or FP (arm B).
  • CONCLUSION:   We could not make any conclusion about the benefit of adding radiation to adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Liver Neoplasms / therapy. Lymph Node Excision. Ovarian Neoplasms / therapy. Peritoneal Neoplasms / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Capecitabine. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Gastrectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Asia Pty Ltd.
  • [CommentIn] Asia Pac J Clin Oncol. 2011 Jun;7(2):93-5 [21585687.001]
  • (PMID = 21114777.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Tomizawa Y, Ishihara S, Iijima H, Imai H, Sato K, Yatomi M, Iwasaki Y, Yamada H, Kobayashi G, Ishida E, Inoue T, Aoki H, Watanabe S, Kawashima O, Mori M, Saito R: A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer. Am J Clin Oncol; 2007 Oct;30(5):498-502
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.
  • OBJECTIVE: We conducted a phase I dose escalation study to determine the maximum tolerated dose, recommended dose, and safety profile of a biweekly gemcitabine and carboplatin combination regimen in the treatment of patients with completely resected nonsmall cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Patients with completely resected pathologically documented stage IB, II, or IIIA NSCLC, performance status (ECOG) 0-1, with adequate bone marrow, renal, liver, and cardiac functions, were treated with gemcitabine and carboplatin.
  • The starting dose was gemcitabine 800 mg/m2 on days 1 and 15 and carboplatin area under the time-concentration curve (AUC) 4 mg/mL/min on day 1.
  • The dose-limiting toxicity of the regimen was assessed during the first chemotherapy cycle.
  • Considering treatment continuation, the recommended dose for a phase II study is gemcitabine 1000 mg/m2 on days 1 and 15 and carboplatin AUC 5 on day 1, every 4 weeks.
  • Biweekly administration of gemcitabine and carboplatin is a feasible and well-tolerated regimen for the treatment of patients with completely resected NSCLC as adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hematologic Diseases / epidemiology. Humans. Leukopenia / chemically induced. Life Expectancy. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17921710.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Suntharalingam M: Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Ann Thorac Surg; 2010 Jan;89(1):200-6; discussion 206
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation.
  • BACKGROUND: We studied the clinical characteristics and outcomes of patients undergoing pneumonectomy after preoperative concurrent chemoradiation for non-small cell lung cancer.
  • METHODS: Clinical records of patients with non-small cell lung cancer who underwent pneumonectomy at our institution between 1995 and 2005 after preoperative concurrent chemoradiation were reviewed retrospectively.
  • Of the 21 men and 8 women who were treated, 1 had stage IIB (T3N0M0) and the remainder had stage IIIA or IIIB non-small cell lung cancer.
  • Mean total radiation dose was 61.1 Gy.
  • Recurrences have been found in 11 patients (38%), including brain metastases (n = 6), bone metastases (n = 4), liver metastases (n = 2), and cervical lymph node metastases (n = 2).
  • One patient had a contralateral new primary lung cancer develop 70 months after undergoing pneumonectomy.
  • Median survival time has not been reached.
  • The frequency of disease recurrence in the brain underscores the need to evaluate the role of prophylactic cranial radiation in non-small cell lung cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiation Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20103235.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Mitsuyama S, Anan K, Ono M: [A case of recurrent breast cancer successfully treated with capecitabine monotherapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1153-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent breast cancer successfully treated with capecitabine monotherapy].
  • A 51-year-old woman underwent pectoralis-preserving mastectomy for right breast cancer (squamous cell cancer, f, T1c, ly0, v0, N2 (18/33), p53 (3+), HER2 (2+), ER (-), PgR (-), T1cN2M0 (Stage IIIA) in March 2001, and received systemic chemotherapy using doxorubicin combined with cyclophosphamide, followed by paclitaxel.
  • After chemotherapy, radiotherapy was added to the chest wall, supraclavicular and parasternal regions.
  • In March 2002 (disease-free interval of one year), liver metastasis was revealed.
  • Systemic therapy using docetaxel, and hepatic artery infusion therapy with epirubicin following docetaxel, failed.
  • Since June 2003, capecitabine monotherapy (2,400 mg/day) was initiated for the liver and lymph node metastases in the mediastinum and retroperitoneum.
  • This therapy is being continued (18 cycles), and no serious side effects have been encountered.
  • Capecitabine monotherapy is safe and very useful for recurrent breast cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local
  • [MeSH-minor] Capecitabine. Female. Fluorouracil / analogs & derivatives. Humans. Liver Neoplasms / secondary. Mastectomy, Modified Radical. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121919.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Puertolas T, Grandez R, Ruiz de Lobera A, Lao J, Herrero A, Martinez Trufero J, Pazo R, Alonso Orduña V, Artal Cortes A, Anton Torres A: Phase II trial of docetaxel plus doxorubicin and cyclophosphamide in locally advanced breast cancer (LABC). J Clin Oncol; 2004 Jul 15;22(14_suppl):855

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel plus doxorubicin and cyclophosphamide in locally advanced breast cancer (LABC).
  • : 855 Introduction: It has been show that patients achieving a pathological complete response to primary chemotherapy benefit in terms of prolonged overall survival (NSABP B18).
  • Docetaxel (D) plus doxorubicin (d) is a highly active combination in metastatic breast cancer (Mackey JR, Proc ASCO 2002) as well as in the neo-adyuvant setting (Ian C, JCO 2002).
  • A three-drug combination could improve these results.
  • METHODS: In this study, females diagnosed of stage II-III LABC between May 2001 to October 2003 with 18-75 years, PS 0-1, and adequate renal, liver and hematological functions were included.
  • Chemotherapy schema (TAC): D 75 mg/m2, Cyclophosphamide 500 mg/m2 and d 50 mg/m2 on day 1, every 21 days plus G-CSF days 5<sup>th</sup> to 11<sup>th</sup>.
  • Four to six courses (c) were scheduled and assessment for clinical response (CR) was made after 2<sup>nd</sup>, 4<sup>th</sup> and 6<sup>th</sup> c.
  • Patient characteristics: median age 53 years (39-73); 25p had PS=0 (75,7%); 36,4% presented with stage IIA, 30,3% stage IIB, 30,3% stage IIIA, and 3,0% stage IIIB; 27p had ductal invasive histology and 6p had a lobular invasive cancer; ER were positive in 22p (66,6%) and negative in 11 p (33,4%); c-erb-B2 was +++/+++ in 7p (21,2%), ++/+++ in 9p (27,3%) and negative in 17p (51,5%).
  • Chemotherapy: 137c were given (median 4 c/p).
  • CONCLUSIONS: This phase II study of TAC as induction chemotherapy in patients with LABC showed a high (both clinical and pathological) response rate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kwon HC, Kim MC, Kim SH, Kim JS, Lee HS, Choi SR, Jeong JS, Jung GJ, Kim HJ: Postoperative adjuvant chemoradiation using oral capecitabine and 5-fluorouracil, cisplatin (FP) in completely resected locally advanced gastric cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant chemoradiation using oral capecitabine and 5-fluorouracil, cisplatin (FP) in completely resected locally advanced gastric cancer.
  • : 4141 Background: Gastric cancer is the most common cancer in Korea.
  • We attempted to evaluate the efficacy and toxicity of FP before and after postoperative chemoradiation using oral capecitabine in locally advanced gastric cancer patients.
  • METHODS: Patients with gastric cancer staged IIIA to IV-M0 were treated with chemoradiation after curative resection with extensive (D2) lymph node dissection.
  • Therapy consisted of one cycle of FP (5-FU 1000 mg/m<sup>2</sup> continuous infusion on day 1-5, cisplatin 60 mg/m<sup>2</sup> on day 1) followed by 4,500 cGY (180 cGy/day) to RT field with capecitabine (1,650 mg/m<sup>2</sup>/day throughout radiation).
  • One month after completion of radiotherapy, patients received three additional cycles of chemotherapy.
  • The patient's stage were IIIA(12), IIIB(6), and IV-M0(3).
  • With a median follow-up of 14.2 months, two patients (9.5%) have relapsed, one in liver and the other in peritoneum.
  • There was no grade 3/4 hand foot syndrome, and no patient has developed febrile neutropenia.
  • There has been no treatment related deaths.
  • CONCLUSIONS: These preliminary results suggest that postoperative regimen of FP and chemoradiation with capecitabine is a safe, well-tolerated in gastric cancer patients who have undergone a D2 dissection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014543.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Addeo A, Dongiovanni V, Birocco N, Dongiovanni D, Fissore C, Buffoni L, Numico G, Bertetto O: Patterns of metastasis, response to treatment and survival in young patients with advanced non small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7343

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of metastasis, response to treatment and survival in young patients with advanced non small cell lung cancer (NSCLC).
  • : 7343 Background: We analysed our cancer registry to determine the clinicopathologic characteristics, response to treatment and survival rates of NSCLC patients under 50 years of age at diagnosis.
  • Pts characteristics: male/female, 29/18; 9 pts were <40 years old; stage IIIA, IIIB, IV in 7/5/35; histological type: adenocarcinoma 18 pts (38%), NSCLC not specified 19 (40%).
  • Radical treatment were applied only to 7 patients: chemoradiotherapy in 4 and chemosurgery in 3 pts.
  • In pts with stage IV disease 46% had brain mts at the diagnosis, 34% bone mts, 29% liver mts, 23% adrenal mts and 50% presented multiple mts sites at diagnosis.
  • All patients were treated with first line chemotherapy: at the beginning of treatment ECOG-PS was 0/1/2 in 8/35/4; platinum-based doublets were administered in 90% of the patients.
  • Median time to progression and survival were 2.8 and 10 months, respectively.
  • Second-line chemotherapy was administered to 23 pts (49%): 14 pts were treated with taxanes.
  • CONCLUSIONS: Patients younger than 50 years with advanced/metastatic disease present data of response to chemotherapy, time to progression and survival comparable to older patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Koussis H, Scola A, Maruzzo M, Ghiotto C, Orvieto E, Bozza F, Zavagno G, Jirillo A: Triple negative breast cancer: Adjuvant treatment and outcome of 62 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e11636

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple negative breast cancer: Adjuvant treatment and outcome of 62 patients.
  • : e11636 Background: Triple negative breast cancer (TNBC) represents around 12-20%.
  • To provide further insight we have undertaken a comprehensive multi year review of demographics tumor features adjuvant treatment and outcomes in this patients group.
  • METHODS: A retrospective analysis of all patients with TNBC treated by adjuvant chemotherapy between January 2000 and June 2008 was done though chart review.
  • Forty-three patients underwent conservative breast cancer surgery, mastectomy 19 patients.
  • The stage of the disease at diagnosis was: I in 22, IIA in 22, IIB in 8, IIIA in 4, IIIB in 2 and stage 0 in 4 patients.
  • After multidisciplinary evaluation 58 patients received adjuvant treatment with: anthracycline based regimen in 30, anthracycline plus taxane in 4 and 24 patients were treated with Cyclophosphamide, methotrexate and 5-Fluorouracil (CMF) regimen.
  • The pattern of disease spread was: local recurrence 5, lymph node 1, liver 2 patients.
  • CONCLUSIONS: Treatment options for TNBC are limited because of lack of targeted treatment.
  • Current, old and new drugs alone or in combination (anthracycline, taxanes, platinum salts, bevacizumab, erlotinib, dasatinib, cetuximab) are used in an experimental setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961189.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Camps C, Caballero C, Garde J, Juarez A, Blasco A, Berrocal A: Weekly paclitaxel as second/third line chemotherapy for advanced and metastatic non-small cell lung cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):7311

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel as second/third line chemotherapy for advanced and metastatic non-small cell lung cancer.
  • : 7311 Background: to evaluate the efficacy and toxicity of weekly paclitaxel as second or third line chemotherapy in patients with advanced or metastatic NSCLC Methods: It's a descriptive and retrospective study of patients with advanced or metastatic NSCLC treated in second or third line chemotherapy with weekly Paclitaxel (60 - 80 mg/m2) until progression or unacceptable toxicity.
  • The histologycal types were 17 patients (45,9%) adenocarcinoma, 12 patients (32,4%) Squamous cell, 7 patients (18'9%) undiffereciated cell and 1 patient (2,7%) adenosquamous.
  • Sixteen patients (43,2%) had stage IIIB disease, 2 (5,4%) stage IIIA and 19 patients (51,4%) stage. IV disease.
  • The metastasis was located in 6 patients (33,3%) in the liver, 4 (22,2%) adrenal gland and 3 patients (16,6%) lung and bone.
  • Thirty-six patients (97,3%) received a first chemotherapy line based on platinum and 1 patient (2,7%) without platinum.
  • The median survival time was 38 weeks (13,6-62,4) and the median time to disease progression was 12 weeks (10,45-13,55).
  • CONCLUSIONS: These data point out weekly paclitaxel as an active and well tolerated agent at second/ third line chemotherapy for advanced NSCLC No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Nakamura T, Fuwa N, Kodaira T, Tachibana H, Tomoda T, Nakahara R, Inokuchi H: Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy. Lung; 2008 Mar-Apr;186(2):91-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy.
  • Primarily combined radiotherapy and chemotherapy are used to treat unresectable non-small-cell lung cancer; however, the results are not satisfactory.
  • In this study treatment results were retrospectively analyzed and the prognostic factors related to survival were identified.
  • From March 1999 to January 2004, 102 patients with stage IIIA/IIIB non-small-cell lung cancer received definitive radiotherapy with or without chemotherapy.
  • Radiotherapy involved a daily dose of 1.8-2.0 Gy five times a week; 60 Gy was set as the total dose.
  • Maximal chemotherapy was given to patients with normal kidney, liver, and bone marrow functions.
  • At the time of the last follow-up, 21 patients were alive and 81 patients had died, including 5 patients who had died due to radiation pneumonitis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prognosis. Radiation Pneumonitis / prevention & control. Retrospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1144-51 [15718310.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2692-9 [10561343.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3454-60 [12177106.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 2003 Nov;63(9):533-8 [14699861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9 [10487552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):110-5 [12504042.001]
  • [Cites] Chest. 2000 Feb;117(2):358-64 [10669675.001]
  • [Cites] Cancer. 1982 Sep 15;50(6):1091-9 [6286087.001]
  • [Cites] Ann Intern Med. 1996 Nov 1;125(9):723-9 [8929005.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • (PMID = 18097718.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; RSA8KO39WH / Vindesine
  •  go-up   go-down


20. Loizzi V, Rossi C, Cormio G, Cazzolla A, Altomare D, Selvaggi L: Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):26-31
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of hepatic metastasis in patients with ovarian cancer.
  • The purpose of this study was to investigate the clinical features of hepatic metastasis in patients with epithelial ovarian cancer.
  • From 1998 to 2002, all women with hepatic metastasis from ovarian cancer were identified at the University of Bari.
  • Twenty-nine patients identified included one having stage IIC, one stage IIIA, two stage IIIB, 17 stage IIIC, and eight stage IVB.
  • Eight women had hepatic metastasis at the time of the diagnosis of ovarian cancer (group I), 10 patients had hepatic metastasis as first recurrence (group II), and 11 (group III) as a second relapse.
  • The median survival from the time of liver metastasis diagnosis was 19 months in group I patients, 24 months in group II patients, and 10 months in group III patients.
  • Cell type, performance status at the time of the primary tumor diagnosis, number of hepatic lesions, the presence of other sites of disease at the time of hepatic metastasis, and platinum-based chemotherapy were significantly related to survival.
  • Better performance status, serous cell-type tumor, single hepatic lesion, the absence of other sites of disease, and platinum-based chemotherapy are good prognostic factors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Neoplasm Recurrence, Local. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670293.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Seshimo A, Kamio T, Aratake K, Ogawa S, Oochi T, Aoyama K, Itabashi M, Shirotani N, Kameoka S: [Radiofrequency ablation of liver metastasis from breast cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1676-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiofrequency ablation of liver metastasis from breast cancer].
  • As the hepatic metastasis from breast cancer has a tendency to have an extrahepatic lesion, systemic therapy therefore becomes acclimatization.
  • However, local therapy is regarded as one of the choices if there is no extrahepatic lesion.
  • We present three cases of liver metastasis from the breast treated by radiofrequency ablation (RFA).
  • Radiation exposure was performed for lung metastasis, and a weekly paclitaxel therapy was administered in 2001.
  • We performed RFA percutaneously for liver metastasis of 2.8 cm in 2002.
  • The liver metastasis finally enlarged to 4 cm in size.
  • Case 2: A 36-year-old woman was treated by left mastectomy (Stage IIIa), and was followed by chemotherapy in 2000.
  • We performed RFA for metastasis of 2 cm of liver (S7) percutaneously in 2001, and didn't recognize a recurrence to date for 3 years and 8 months.
  • Case 3: A 43-year-old woman was treated by left mastectomy (Stage IIIa), and followed by chemotherapy in 2003.
  • We performed RFA for a liver metastasis of 3.5 x 4 cm under laparotomy in 2004.
  • [MeSH-major] Breast Neoplasms / pathology. Catheter Ablation. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315906.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Sato T, Sato S, Kato K, Tsunozaki H, Iwama T, Karasawa K, Takahashi T: [Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1904-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer].
  • We present two cases of liver metastases from breast cancer treated by radiofrequency ablation (RFA) for elongation of life.
  • Case 1: A 50-year-old woman was treated by left mastectomy (stage IIIa) in December 2002.
  • In April 2004, she was treated with a combination therapy of weekly paclitaxel and trastuzumab for multiple liver metastases, left supraclavicular lymph node metastases, and multiple bone metastases.
  • After 16 courses of weekly paclitaxel and trastuzumab, liver metastases decreased significantly in size.
  • Because liver metastases recurred during a continuation of weekly paclitaxel and trastuzumab, we performed RFA and chemotherapy using a hepatic artery infusion of docetaxel for liver metastasis.
  • The aggravation spread to the liver lesion and she died after 20 months from liver metastases.
  • Case 2: A 65-year-old woman was treated by left mastectomy (stage IIA) in 1984, and the distant metastasis was not found through the course after an operation.
  • She was noted with a liver function aberration in another hospital in March 2005.
  • We scanned it, and it was diagnosed as multiple liver and bone metastases from breast cancer.
  • Because she did not hope for an anticancer drug treatment for multiple liver metastases, we performed RFA in May 2005.
  • After the second RFA was performed, she does not show any new lesion to the liver for 10 months.
  • [MeSH-major] Breast Neoplasms / pathology. Catheter Ablation. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Fatal Outcome. Female. Hepatic Artery. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Mastectomy. Middle Aged. Paclitaxel / administration & dosage. Taxoids / administration & dosage. Trastuzumab

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212142.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 15H5577CQD / docetaxel; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Ishizuka T, Yoshiyasu M, Yanagi K, Bando K, Yoshimura K, Tajiri T: [A patient with hepatic, pulmonary, and nodal metastases of colon cancer responding to CPT-11/TS-1 therapy]. Gan To Kagaku Ryoho; 2006 Jun;33(6):821-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with hepatic, pulmonary, and nodal metastases of colon cancer responding to CPT-11/TS-1 therapy].
  • In December 2002, a 67-year-old man underwent right colectomy (stage IIIa, cur B) for cancer of the ascending colon.
  • Chemotherapy with 5'-DFUR and PSK was performed after surgery, but was discontinued due to grade 3 diarrhea.
  • The patient refused treatment with other drugs.
  • An increased CEA level was observed in July 2004, and metastasis of his colon cancer to the liver, lungs, and supraclavicular lymph nodes was confirmed.
  • The patient agreed to resume chemotherapy in December 2004, and received outpatient treatment with CPT-11 (70 mg/m(2) on days 1 and 8) and TS-1 (100 mg/day on days 1-14).
  • Diarrhea (grade 1) and oral ulceration (grade 2) were observed during treatment.
  • However, these side effects were transient and resolved temporarily without suspending therapy.
  • Although hepatic dysfunction (grade 2) was observed after the completion of cycle No.5, the patient decided to discontinue treatment.
  • CPT-11/TS-1 chemotherapy seems to be useful for maintaining the QOL of patients with metastatic colon cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colectomy. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Humans. Lymphatic Metastasis. Male. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770105.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. Takahashi T, Kochi M, Kanamori N, Kaiga T, Fujii M, Takayama T: [Successful treatment with S-1 + CPT-11 for hepatic metastasis from gastric cancer--a case report]. Gan To Kagaku Ryoho; 2010 Jan;37(1):157-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with S-1 + CPT-11 for hepatic metastasis from gastric cancer--a case report].
  • The patient was a 67-year-old male with Type 3 gastric cancer who underwent distal gastrectomy and D2 dissection in December 2004.
  • It was diagnosed to be a cancer of se, n(1+), Stage IIIA.
  • The tumors were diagnosed as multiple hepatic metastases of the gastric cancer.
  • After 5 courses of concomitant S-1+CPT-11 therapy, abdominal CT in February 2007 showed complete elimination of the multiple tumors in both hepatic lobes, and it was considered that a complete response (CR) had been obtained.
  • After initiation of the treatment, 32 courses of S-1+CPT-11 therapy were performed, and at present, 24 months after the therapy, the patient has survived with no redevelopment of the cancer.
  • All of the treatments were performed in an outpatient setting, and no side effects have been confirmed other than grade 1 gastric and skin symptoms.
  • We experienced a case in which CR was achieved by S-1+CPT-11 therapy in a patient with hepatic metastasis of a gastric cancer.
  • [MeSH-major] Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Combinations. Gastrectomy. Humans. Male. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087053.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Yuasa Y, Okitsu H, Seike J, Ishikura H, Ichimori T, Ishikawa M, Kimura S, Sakata A: [A case of rectal cancer treated by preoperative chemoradiation]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1973-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of rectal cancer treated by preoperative chemoradiation].
  • Further examination revealed that advanced rectal cancer which invaded to presacral space (Ai, N 0, P 0, H 0, M(-), stage IIIa) caused such symptom.
  • In addition we underwent radiation 2.4 Gy/day and intravenous low-dose cisplatin (CDDP) 5 mg/day, 5 days/week for 3 weeks.
  • The specimen revealed that no malignant lesion remained, which changed to necrotic tissue.
  • For example, diarrhea, nausea, and mucosal dysfunction were each less than grade 2, and there was much tolerate for renal, liver, and bone marrow function.
  • This combination chemoradiotherapy is considered to be effective for locally advanced rectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Colostomy. Drug Administration Schedule. Drug Combinations. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Preoperative Care. Rectum / surgery. Remission Induction. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282738.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Matsuyama Y, Tominaga T, Nomura Y, Koyama H, Kimura M, Sano M, Miura S, Takashima S, Mitsuyama S, Ueo H, Ohashi Y: Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol; 2000 Dec;11(12):1537-43
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan.
  • BACKGROUND: Women treated with tamoxifen for breast cancer are at increased risk of endometrial cancer.
  • We conducted a retrospective cohort study to evaluate the risk of second primary cancers after adjuvant tamoxifen therapy for breast cancer in Japan.
  • PATIENTS AND METHODS: The subjects of the study were 6148 women who had been diagnosed with stage I, II, or IIIA unilateral primary breast cancer and had received surgical treatment during the period from January 1982 through December 1990 at nine institutions in Japan.
  • RESULTS: Of the 6148 women, 3588 (58.4%) were administered tamoxifen as an adjuvant treatment and 2560 (41.6%) were not administered.
  • The duration of tamoxifen treatment was mostly two years or less (80.7%), and few patients received tamoxifen for more than five years.
  • Of the 12 patients who developed endometrial cancer, 4 died of cancer (for 3 of them, the cause of death was breast cancer), and the other 8 patients were alive as of March 1996.
  • Stomach cancer was the most frequent second cancer and the IRR was 1.34 (95% CI: 0.76-2.38, P = 0.31).
  • There was no substantial increase in any other type of gastrointestinal cancer such as colorectal and liver cancers among tamoxifen-treated patients.
  • CONCLUSIONS: The incidence and risk of second primary cancers associated with tamoxifen therapy is low.
  • The potential benefit of adjuvant tamoxifen therapy in breast cancer patients outweighs the risk of second primary cancers for Japanese breast cancer patients.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205460.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


27. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, Graeter T: Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer; 2009 Apr;64(1):71-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma.
  • The prognostic relevance of blood vessel invasion (BVI) in non-small cell lung carcinoma (NSCLC) remains controversial, as is the question of whether its finding should influence therapeutic decisions after an R0 resection.
  • In all cases, lymphatic metastatic spread was at its earliest stage and only one regional lymph node was involved, 27.0+/-8.9 nodes per patient being examined histologically.
  • 62.5% were at stage IIB, 25.9% at stage IIIA, and 9.8% at stage IIA.
  • Thus 31.2% of the patients developed distant metastases by hematogenous spread (to the brain, bones, lung, adrenal, and liver, in descending order of frequency), mostly within two years of surgery.
  • Adenocarcinomas showed a strong tendency to be associated with a poorer prognosis than squamous cell carcinomas, probably because of their more frequent involvement of blood vessels.
  • The histological detection of BVI is of prognostic relevance and should be considered for inclusion in the staging criteria and indications for adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790545.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


28. Kosmas C, Tsavaris NB, Polyzos A, Kalofonos HP, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ: A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma. Cancer; 2000 Aug 15;89(4):774-82
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
  • BACKGROUND: The necessity to develop more effective chemotherapy regimens in advanced nonsmall cell lung carcinoma (NSCLC) prompted the authors to evaluate the paclitaxel-ifosfamide-cisplatin (PIC) combination, developed on the basis of high individual single-agent activity, in vitro synergism, and tolerance as determined in a previous Phase I study by the authors.
  • PATIENTS: Eligibility criteria included advanced NSCLC (American Joint Committee on Cancer [AJCC]/International Union Against Cancer [UICC] Stage III/IV), Eastern Cooperative Oncology Group performance status (PS) </= 2, no prior chemotherapy, and unimpaired hematopoietic and organ function.
  • Chemotherapy included, paclitaxel 175 (in the first 10 patients) or 200 mg/m(2) on Day 1, ifosfamide: 5 g/m(2) divided over Days 1 and 2, and cisplatin 100 mg/m(2) divided over Days 1 and 2, recycled every 21 days.
  • RESULTS: Fifty patients were entered, and all were evaluable for response and toxicity: median age, 58 years (range, 40-72), PS, 1 (range, 0-2), Gender: 44 males and 6 females, Stages IIIA, 6 patients; IIIB, 17; IV, 27; histologies: adenocarcinoma, 27 patients; squamous, 17; large cells, 5; unspecified, 1.
  • Metastatic sites at diagnosis included lymph nodes, 33 patients; bone, 6; liver, 5; brain, 10; lung nodules, 7; adrenals, 6; other, 2.
  • The median response duration was 7 months (range 2-34+); median time-to-progression, 8 months (range, 1-36+), median overall survival, 12 months (range, 2-36+).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Patient Compliance. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10951340.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


29. Tsuchiya T, Hiramatsu K, Tanaka H, Machiki Y, Sakuragawa T, Otsuji H, Hara T, Kimura A, Yoshida K, Hosoya J, Kojima T, Kato K: [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2641-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
  • A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion.
  • He was diagnosed with advanced gastric cancer, T3N1H0P0M0, Stage IIIa.
  • The pathological diagnosis was gastric endocrine cell carcinoma because Grimelius and Chromogranin A stained positive histologically.
  • Seven months after operation, recurrent liver metastases with tumor embolism of the portal vein were revealed by enhanced CT examination.
  • FU (5-FU/UFT) +CPT-11 was done as the first-line adjuvant chemotherapy.
  • Metastatic lesion of the liver and portal vein tumor embolism was decreased.
  • This therapy was evaluated as a partial response (PR) in twelve months and the patient died three years and eight months after operation.
  • Gastric endocrine cell carcinoma is known as a potentially highly malignant tumor.
  • Based on this finding, we recommend adjuvant chemotherapy by FU+CPT-11 for gastric endocrine cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Gastrectomy. Humans. Lymph Node Excision. Male. Neoplasm Metastasis. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009471.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


30. Tanaka A, Honma K, Kondo H: [A case of cerebellum metastasis from colon cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2242-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cerebellum metastasis from colon cancer].
  • We report a case of cerebellum metastasis from transverse colon cancer, which had no evidence of recurrence in the thoracoabdominal region by chemotherapy and resection of liver and lung metastases after initial operation.
  • We performed a radical resection of transverse colon cancer (D2) in 2001.
  • The finding was moderately-differentiated adenocarcinoma, se, n1, ly1, v2, H0, P0, M0, stage IIIa.
  • Relapsing tumor, which metastasized to the liver in 3 years, the right lung in 4 years and 8 months and the left lung in 5 years and 11 months after initial operation, were totally resected.
  • Following the partial resection of the left lung, he received a treatment with 12 times of mFOLFOX6 and S-1+PSK.
  • However, drift and dizziness developed in April 2008, and cerebellum metastasis was diagnosed by MRI.
  • He underwent a partial resection of cerebellum tumor, radiation therapy and FOLFIRI.
  • He has been alive for 1 year after the treatment of the cerebellum metastasis, and there has been no evidence of recurrence in the thoracoabdominal region in 8 years after initial operation.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037383.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement